Drug Profile

RAD 204

Alternative Names: RAD-204

Latest Information Update: 20 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Radiopharm Theranostics
Class Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 May 2025 Data and Safety Monitoring Committee (DSMC)recommends proceeding of RAD 204 in phase I trial for Non small cell lung cancer in Australia
22 May 2024 Phase-0 for Non-small cell lung cancer in Australia (unspecified route) (NCT06305962)
21 Dec 2023 Radiopharm Theranostics plans a phase I trial for Non-small cell lung cancer in Australia in March 2024 (Radiopharm Theranostics pipeline, December 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com